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Abstract  
 
Background: Circadian timing of treatments can largely improve tolerability and efficacy in 
patients. Thus, drug metabolism and cell cycle are controlled by molecular clocks in each cell, 
and coordinated by the core body temperature 24-hour rhythm, which is generated by the 
hypothalamic pacemaker. Individual circadian phase is currently estimated with 
questionnaire-based chronotype, center-of-rest time, dim light melatonin onset (DLMO), or 
timing of CBT maximum (acrophase) or minimum (bathyphase). 
Methods: We aimed at circadian phase determination and read-out during daily routine in 
volunteers stratified by sex and age. We measured (i) chronotype; (ii) q1min CBT using two 
electronic pills swallowed 24-hours apart; (iii) DLMO through hourly salivary samples from 
18:00 to bedtime; (iv) q1min accelerations and surface temperature at anterior chest level 
for seven days, using a tele-transmitting sensor. Circadian phases were computed using 
cosinor and Hidden-Markov modelling. Multivariate regression identified the combination of 
biomarkers that best predicted core temperature circadian bathyphase.  
Results: Amongst the 33 participants, individual circadian phases were spread over 5h10min 
(DLMO), 7h (CBT bathyphase) and 9h10 min (surface temperature acrophase).  CBT 
bathyphase was accurately predicted, i.e. with an error <1h for 78.8% of the subjects, using a 
new digital health algorithm (INTime), combining time-invariant sex and chronotype score, 
with computed center-of-rest time and surface temperature bathyphase (adjusted R-squared 
= 0.637).  
Conclusion: INTime provided a continuous and reliable circadian phase estimate in real time. 
This model helps integrate circadian clocks into precision medicine and will enable treatment 
timing personalisation following further validation. 
Funding: MRC, UK; AP-HP Foundation and INSERM, France.   
 4 
Text 
Introduction  
The discovery of the molecular mechanisms of circadian clocks has highlighted a new 
potential for improving human health through the translation of circadian timing concepts to 
medical practice(1-3). In mammals, a molecular oscillator involving 15 clock genes generates 
an about 24-hour oscillation that rhythmically regulates cellular metabolism, division, and 
death within each cell(2, 4, 5).  The molecular clocks in the cells of all organs are coordinated 
by an array of physiological rhythms that are generated by the suprachiasmatic nuclei (SCN) 
in the hypothalamus(6). Thus, the circadian phase of SCN function constitutes a critical 
measure for inferring timing throughout the organism. The circadian rhythm in core body 
temperature and that in circulating glucocorticoids, which are controlled by the SCN, play a 
key role in the coordination of the molecular clocks outside the brain(7-9), while the 
melatonin secretion rhythm both informs on the circadian phase of the SCN, and helps 
calibrate its period(10).  The rest-activity circadian pattern, which integrates lifestyle and 
social signals, has bidirectional linkage with the SCN, thus can moderate the robustness of SCN 
rhythmic functions in rodents(11).  The circadian timing system (CTS) involves the several 
components that generate, moderate or reset the circadian rhythms at cellular, tissue or 
whole body levels, including the retinal light sensor melanopsin, the SCN, the SCN-generated 
circadian physiology, and the network of molecular clocks in all organs and tissues(2). Studies 
in healthy humans and in patients with cancer or other diseases have revealed large between-
subjects differences for the rhythms in rest-activity(12, 13), body temperature(13), circulating 
cortisol(14), and melatonin levels(15), as well as those in clock gene expression in peripheral 
tissues(16). More specifically, the extent of the circadian variations (double-amplitude of the 
fitted 24-hour cosine function) in the physiological biomarkers varied by up to several-fold, 
and the timing of maximum (acrophase) or minimum (bathyphase) by up to 12-h in humans 
studied during their daily routine(12-16). Occupational schedules can also impact on health, 
through altering circadian timing system (CTS) function. For instance, night shift work that 
causes circadian disruption was identified as increasing the risks of breast and possibly other 
cancers, as well as cardio-vascular, gastro-intestinal, metabolic, and reproductive 
disorders(17-19). Recently, circadian rhythm research has reached a critical level where 
translational applications to human health have become fundamental for many 
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conditions(20, 21). It is clear that treatment timing can largely affect the occurrence of 
adverse events and efficacy, thus making the consideration of individual differences in CTS 
function essential for the proper care of patients. Such time dependencies have been 
demonstrated in randomized clinical trials and meta-analyses involving patients with 
malignant, cardio-vascular, rheumatologic, or neurodegenerative diseases(20, 22-25). 
Similarly, the daily timing of preventive interventions also appeared critical, as shown for 
vaccination(26). Experimental and clinical studies have further indicated that patients on 
antibiotics or analgesic medications could benefit from circadian timing optimization of their 
treatment(2). However, human physiology, experimental chronopharmacology, and clinical 
chronotherapy trial data have revealed sex-dependent differences in CTS function and 
stressed their clinical relevance(23, 27). For instance, overall survival was improved 
significantly in men but not in women receiving the same fixed time chronomodulated 
chemotherapy protocol with oxaliplatin and 5-fluorouracil-leucovorin for metastatic 
colorectal cancer as compared to conventional delivery, as demonstrated in a meta-analysis 
of three international randomized trials involving individual patient data(23).  
Thus, it is necessary to reliably determine the circadian phase in real time for each patient, 
using a non-invasive and simple method, in order to fulfil the promises resulting from the 
discovery of circadian clocks mechanisms for precision medicine. Novel diagnostic tools have 
to be developed that aim both at the prevention of circadian disorders, that can lead to 
chronic diseases or their exacerbation, and at the personalization of clock-based therapies for 
cancers and other chronic diseases.  
Toward this goal, the current study aimed at the continuous and remote determination of the 
individual subject’s bathyphase (timing of the computed daily nadir) of the overt 24-hour 
rhythm in core body temperature. New digital health method and algorithm were designed 
here for computing internal circadian phase (INTime) in people whose circadian rhythms were 
tele-monitored in real time during their daily routine.  
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Results 
Subjects’ characteristics and chronotype 
Of the 37 recruited participants, 33 provided valid data, including 15 males and 18 females, 
aged 21 to 78 years, with a similar distribution according to age (Figure 1, Table S1). The 
majority of participants had no ongoing medical condition and were not taking any 
medication. Oral contraceptive pills or intrauterine systems were used by 39% of the female 
participants.  
The morningness-eveningness questionnaire scores revealed that chronotype was 
categorized as “morning” for 15 subjects, “intermediate” for 15 other and “evening” for three 
participants.  
Dim Light Melatonin Onset 
Adequate saliva samples were available for 24 of 30 subjects assessed for this endpoint (80%). 
Salivary melatonin data were available for computing Dim Light Melatonin Onset (DLMO) 
using a threshold based on individual baseline values for 12 participants (40%) (Figure 2A). 
The estimated threshold method based on the pooled 34 baseline values in the same subjects 
was also applied. Individual DLMOs using both methods differed by -32 min to +11 min, and 
were strongly correlated (Pearson’s correlation, r = 0.96, p < 0.001). Thus, we used the 
estimated threshold method to compute the DLMOs of the 24 subjects. The median clock 
hour of melatonin secretion onset occurred at 20:50 with an Inter-Quartile Range (IQR) of 
[20:01 to 21:19] and individual values spread over 5h10 min (Figure 2B).  
Core body temperature 
Overall, core body temperature time series were provided by both e-Celsius pills in each 
subject for a median time span of 2.9 days [IQR, 2.0-3.4], ranging from 1.3 up to 14.4 days 
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according to individual gastro-intestinal transit. Each of the 66 pills ingested by the 33 
participants provided temperature time series over durations ranging from 0.2 to 13.4 days 
(median, 1.6; IQR, 1.1 to 2.4). There was an overlap of 24-h or more for the records by the 
first and second pill in 13 subjects. Raw temperature data from both pills were correlated 
within each of these 13 participants, with a median Pearson correlation coefficient of 0.86 
(IQR, 0.74 to 0.93), that was highest with a time lag of -2 min. 
Our cosinor analysis revealed that most individuals displayed a strong 24-h rhythmic pattern 
occasionally with an additional prominent 12-h component (Figure 2C). We found that the 
precision of the individual bathyphases, as indicated with 90% Confidence Intervals (CI) < 55 
min, was much better than that of the corresponding acrophases, whose CIs largely exceeded 
this value for six subjects (18.2%).  The median acrophase was located at 17:40 [IQR, 15:20 to 
19:05], with individual values staggered over 12h05min. The median bathyphase occurred at 
03:30 [IQR, 2:30 to 4:15], with individual values spread over a 7-h span (Figure 2D). 
Rest-activity and surface temperature tele-transmitted by chest sensor 
Rest-activity and temperature time series from the chest surface sensor were available for 
the 33 participants, for a median duration of 7.0 days [IQR, 6.9 to 7.3]. Large inter-subject 
variations were obvious (Figure 3A). Thus, median number of accelerations per min ranged 
from 6 to 135 between subjects, with highest values reaching 331 up to 538. Median chest 
surface temperature values (5-min aggregates) varied from 32.6 to 36.5°C between 
participants.  
Chest surface temperature lowest daily values in fitted curves from individual participants 
ranged from 32.1 to 36.4°C and highest daily values, from 34.5 to 36.8°C.  
Rest activity time series displayed regular 24-h patterns that were highly reproducible from 
one day to the next in all the subjects, as indicated with prominent 24-h period according to 
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spectral analyses(28). Harmonic HMM analyses(29) revealed that the median center-of-rest 
time was located at 03:05 [IQR, 02:15 to 03:25], with individual values ranging over 5h15min 
(Figure 3B). 
Spectral analyses(13, 28) of chest surface temperature time series identified a dominant 24-
h periodic component for 21 participants (63.6 %), and a dominant 12-h component for nine 
of them (27.3%), resulting in two daily maxima as shown in cosinor fittings (Figure 3C). No 
circadian or 12-h pattern was found for three participants (9.1%). According to our cosinor 
analysis, the median nightly acrophase of chest temperature occurred at 03:00 [IQR, 02:10 to 
03:55], with individual values spread over 9h10min (Figure 3D). The corresponding median 
daily bathyphase that followed the nightly acrophase took place at 11:00 [IQR, 9:40 to 12:35], 
with individual values spread over 10h25min.  
Non-invasive prediction of core temperature bathyphase 
No statistically significant correlation was found between sex, age, BMI or concurrent 
treatment, on the one hand, and the various phase indicators, on the other hand, according 
to two-sample t-test and pairwise Spearman’s correlation (p > 0.10).  In contrast, circadian 
phase estimates were correlated to some extent (Figure S1). The DLMO was weakly 
correlated with the core temperature acrophase (Spearman’s correlation, r=0.40, p=0.05) and 
bathyphase (r=0.36, p=0.09). Chronotype score was strongly correlated with center-of-rest 
time (r=-0.70, p<0.001), chest surface temperature acrophase (r=-0.60, p <0.001), and core 
temperature bathyphase (r=-0.67, p<0.001). The center-of-rest time was further correlated 
with both chest surface and core temperature acrophases (r= 0.67 and r=0.69, respectively; 
p<0.001) and core temperature bathyphase (r=0.71, p<0.001). Stepwise model selection 
identified the ‘best’ regression model for predicting core temperature bathyphase, with an 
adjusted R-squared of 0.637. The resulting model named “INTime” predicted core 
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temperature bathyphase using the covariates sex (p<0.001) and chronotype score (p=0.009) 
as well as two computed phase indicators from the chest sensor data, namely the center-of-
rest time (p=0.033), and chest surface temperature bathyphase (p = 0.063) by means of the 
following estimated equation: 
Core temperature bathyphase = 1.33* sex– 0.058*chronotype score + 0.472*center-of-rest 
time - 0.145 chest temperature bathyphase, with sex being coded as 1 for male and 0 for 
female, and phases in hours and decimal hours. 
The accuracy of the predicted core temperature bathyphase (Figure 4) was computed by the 
distance between the predicted and measured values, whose median was 7 min [IQR, -40min-
31min], with individual errors from -106 to +108 min. As a result, the fitting error was < 1h 
for 26 participants (78.8%). In addition, the 90% prediction bands covered most individuals’ 
measured bathyphase values, i.e. 31-in-33 participants (93.9%), indicating a very satisfactory 
within-sample prediction accuracy.  
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Discussion 
Inter-subject differences in chronotype make it crucial to perform circadian rhythm 
measurements without interfering with the daily life of people, in order to successfully 
translate and broadly apply circadian clock concepts to precision medicine. The current study 
represents an important step toward such goal as it revealed inter-individual differences by 
7h for the bathyphase of core body temperature, by 5h10 min for DLMO, by 5h15 min for 
center-of-rest time, and by 9h10 min for the acrophase of chest surface temperature, thus 
highlighting large inter-subject variability for these distinct and correlated estimates of 
circadian phase. The endogenous circadian rhythms in core body temperature, as 
continuously recorded using a rectal probe(30), and that in circulating melatonin 
concentrations were robustly coordinated in healthy humans. As a result, the bathyphase of 
core body temperature has been largely used as an adequate reference for the endogenous 
circadian phase in humans(31, 32),  based on studies performed under constraining constant 
routine protocols in human chronophysiology laboratories(30, 33). While salivary DLMO at 
home might have proven as a precise indicator of circadian phase, it could only be estimated 
in 80% of our very compliant participants. Reasons involved occasional environmental light 
contamination both outside and at home, possible food contamination by melatonin-
containing ailments, and need for alterations in daily and familial routine, including meal 
timing. To circumvent such drawbacks and to enable clinical applications of circadian clocks, 
the current study has identified a non-invasive method that provides a precise and continuous 
estimate of individual circadian bathyphase of core body temperature in real time from 
remote people during their daily routine. Within-sample accuracy was less than one hour for 
78.8% of the participants. The use of this model in medical practice requires information on 
sex, score from the chronotype questionnaire, and two circadian timing parameters extracted 
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from chest rest-activity and surface temperature monitoring. Both of them are easily 
amenable to automatic real time computation out of tele-transmitted time series being 
recorded during the daily routine of the person. We expect that INTime will enable circadian 
timing of treatments, i.e. chronotherapy, to irreversibly complement the basic principle of 
today’s toxicology “The dose makes the poison”. This paradigm which was proposed by 
Paracelsius some 500 years ago(2) has driven the current adjustment of drug dose levels to 
body weight or surface area, pharmacokinetics, or drug polymorphisms, which have become 
indispensable information for both regulatory approval, and safe medical use of medications. 
Although there is strong evidence that time-of-day of treatment delivery can matter as much 
as dose(2, 3, 22-24, 26, 27), we have been lacking a metrics for the determination of optimal 
treatment timing in individual patients. Indeed, results from randomized clinical trials and 
meta-analyses have shown that the patients’ benefits resulting from drug timing could be as 
large as 5-fold, yet they could depend upon patient’s sex and circadian timing system 
function(23, 27). The need for the personalization of treatment timing was further highlighted 
by up to 8-hours difference in optimal timing of the anticancer drug irinotecan, as a function 
of mouse sex and genetic background. In this large study, optimal timing was predicted by a 
mathematical model combining the circadian mRNA expression patterns of clock genes Bmal1 
and Rev-erbα in liver or colon, which also governed the key pharmacology mechanisms of this 
drug(34, 35).  Recent results have further highlighted consistent relations between 24-hour 
temperature cycles and circadian patterns in metallodrugs toxicity both in vitro and in 
vivo(36).  The findings are in line with previous studies linking the circadian rhythms in mouse 
tolerability for 16 anticancer drugs to the intraperitoneal temperature cycle(37).  
Both the limited sample size available for DLMO estimations and the weak correlations 
between DLMO and other timing indicators precluded any attempt toward the search for a 
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prediction model of DLMO. Moreover, the ability to reset most peripheral clocks with 
physiological temperature cycles but not with melatonin supported a potential key role of 
this rhythm for the biomedical applications of circadian clocks. The limitations of our study 
involve the measurement of core body temperature within various segments of the gastro-
intestinal tract, and the lack of a validation sample of the INTime model. Previous studies have 
shown that the circadian patterns in body temperature measurements were very similar if 
taken from gut using an ingested pill or from rectum using a dedicated probe(38),  thus 
supporting gut temperature bathyphase as a reliable circadian phase biomarker.  Moreover, 
INTime predicted circadian phases to range from 1:55 to 7:05 in a distinct cohort of 18 healthy 
subjects whose sex, chronotype, center-of-rest time, and chest surface temperature 
bathyphase had been determined previously(13). In this independent sample, median, IQR, 
and extremes of predicted individual circadian phases matched very well those in the current 
study (Figure S2), although accuracy could not be computed since core body temperature 
rhythms were not recorded.  By bootstrapping the residuals of the INTime model fit, we 
obtained pseudo datasets with arbitrary size N. By applying 1000 Monte Carlo simulation 
trials, we find that N=600 and N=1000 samples would be required to stabilize the INTime 
model fit so that the corresponding 90% and 95% confidence intervals of the adjusted R-
squared are less than 10% of the given value of 0.637.  
Our findings have a major potential impact for the reduction of severe adverse events from 
treatments, whose reduction represent a critical challenge for improving patient quality of 
life, treatment compliance, treatment efficacy, and human health cost burden. As an 
example, a 10.8-fold increase in the yearly rate of emergency visits for cancer treatment-
related toxicities has been documented over ten years in a large US study, where 91% of the 
 13 
emergency visits translated into emergency admissions, and 4.9% of deaths, resulting in 
related costs of billions of US$(39).  
In conclusion, using a tele-transmitting dual-function chest sensor and INTime, treatment 
timing can be personalized both between and within patients, thus potentially reducing 
adverse events and improving therapeutic outcomes. Such personalized chronotherapy 
deserves prospective testing and could help invert the steadily rising economic burden of 
treatment morbidities in cancer and chronic diseases.  
 
  
 14 
Methods 
Study design and human subjects 
The study aimed at (i) the estimation of the internal circadian phase during daily routine, a 
process that usually requires a constraining circadian physiology protocol in the 
laboratory(30, 33), and (ii) the assessment of the relevance of age and sex on the non-invasive 
circadian biomarkers selected for informing on the CTS during human daily routine (Figure 5). 
We aimed to recruit 30 adult volunteers stratified by sex and age above or below 40 years 
with valid data. 
Eligibility criteria included the ability to work or to perform usual activities and to be aged 18 
years or more. Non-inclusion criteria involved any uncontrolled pathologic or psychological 
condition, any known gastro-intestinal disease, any ongoing treatment with 
glucocorticosteroids, melatonin agonists or antagonists, lithium, or analgesic, any contra-
indication to the use of electronic devices, and night shift work or crossing of more than three 
time zones within the past four weeks. Volunteers were recruited locally through flyers and 
advertisements in newsletters and local journals. The study participants were asked not to 
change their free-living daily schedule throughout the study, except on the evening when they 
were to collect six hourly samples at home in dim light starting at 18:00 until usual bedtime. 
Data collection and processing 
Main characteristics of the subjects, including sex, birth date, marital status, professional 
activity, past and current illnesses and treatments, were recorded upon study entry. Chest 
surface temperature, activity and 3-D orientation were recorded every minute for one week 
using the PiCADo mobile eHealth platform(13). These three variables were measured using a 
chest sensor (Movisens, Karlsruhe, Germany) and a pocket-sized gateway (Eeleo, Montrouge, 
France). Anonymous data were transmitted via Bluetooth from the sensor to the connected 
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gateway and then transmitted to a secure and dedicated server via General Packet Radio 
Service (GPRS) every 24 hours. As the devices used were not waterproof, their short removal 
was allowed for showers, baths or occasional needs. A body weight scale was also connected 
to the gateway via Bluetooth, with daily measurements acquired before breakfast. 
Saliva was self-collected by the participants using saliva collection aids (SalivaBio Passive 
Drool, Salimetrics, State College, Pennsylvania, USA) and 2 mL micro tubes (SARSTEDT AG & 
Co., Nümbrecht, Germany). Participants were asked to collect five hourly samples at home 
during an evening in dim light starting at 18:00 and a sixth one at 23:00 or before retiring, 
whichever came first. Dim light conditions were verified using a wrist actigraph 
(Motionlogger® Micro Watch, Ambulatory Monitoring Inc., Ardsley, NY, USA), with all subjects 
being reminded not to occlude the light sensor with sleeves. A salivary sample was considered 
invalid for melatonin determination, if light intensities > 50 lux(40) had been recorded by the 
wrist watch light detector  within the 30 minutes preceding collection.  
Core body temperature was measured using an electronic ingestible pill (e-CELSIUS 
Performance® pill, BodyCAP Medical, Hérouville Saint-Clair, France). Participants were asked 
to ingest one such pill in the morning for two consecutive days. Data were transmitted via 
Radio Frequency to a dedicated monitor (e-viewer® performance monitor, BodyCAP Medical). 
Data were transferred from the monitor to the computer of the biomedical engineer after 
both pills had been eliminated through the stools. The abnormally low or high core body 
temperature values in the first few hours of recording were deleted as they were typically 
due to the temperature of food or drink ingestion. Data from the first ingested pill were used 
until pill elimination in the feces. Data from the second pill were used thereafter to obtain a 
complete time series. Participants provided a detailed diary with time of awakening and 
retiring, mealtimes, intense activity times, and medication times (if any). 
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Chronotypes were determined using the largely-validated morningness-eveningness self-
assessment questionnaire(41). 
Data Management 
Tele-transmitted chest sensor data were stored on the server based on HL7 standards 
(international standards for transfer of clinical and administrative data). Data were 
downloaded from the server to the computer of the biomedical engineer only. Anonymized 
data were saved on a secure storage server according to the national Data Protection and 
Freedom of Information Acts guidance. Data transmission was inspected at least twice a week 
during the monitoring sessions to insure adequate functioning.  
e-CELSIUS temperature data from the ingestible pills were received on the BodyCAP monitor. 
Similarly, after retrieval of the monitor from the subjects, data were downloaded and saved 
on a secure storage server according to the national Data Protection and Freedom of 
Information Acts guidance.  
Statistical Methods for Quantifying Circadian Rhythmicity 
Salivary Melatonin Secretion 
DLMO is commonly computed as the time when melatonin concentration in plasma or saliva 
exceeds a threshold computed as the mean of three consecutive daytime values before rise 
plus twice the standard deviation of these three points(42). For those subjects with 
insufficient baseline data, an estimated threshold value was computed as the mean plus twice 
the standard deviation of the pooled baseline melatonin values in the subjects with adequate 
baseline data. This estimated threshold was first validated in the subjects with adequate 
baseline data by Pearson correlation, prior to its use for all the subjects. 
Chest Surface Temperature and Core Body Temperature  
A single core temperature time series linked the temperature data measured by the first pill, 
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until its elimination and the second one, afterwards. The temperature data were first 
aggregated by 5-min mean and smoothed using a 1-hour moving average window, then 
computed as an averaged 24-h profile. We further fitted the following two-harmonic cosinor 
model(43), with periods 𝑇1 = 12-h and 𝑇2 = 24-h to describe the average day oscillation of 
both chest surface and core body temperatures based on prior evidence(13): 
𝑦(𝑡) = 𝑀 + 𝑎1 sin (
2𝜋𝑡
𝑇1
) + 𝑏1 cos (
2𝜋𝑡
𝑇1
) + 𝑎2 sin (
2𝜋𝑡
𝑇2
) + 𝑏2 cos (
2𝜋𝑡
𝑇2
) + 𝑒(𝑡)   (1)  
where 𝑦(𝑡) is the temperature at time t; 𝑀 is the mesor (mean level of the fitted cosine 
function); 𝑎1, 𝑎2 and 𝑏1, 𝑏2 are the coefficients of the cosinor model, and 𝑒(𝑡) is the error. 
Given the periods 𝑇1 and 𝑇2, the coefficients were estimated by least-squares linear 
regression. We report the overall acrophase 𝜃𝑚𝑎𝑥, i.e. time of maximal value in the fitted 
values ?̂?(𝑡), and the overall bathyphase 𝜃𝑚𝑖𝑛, i.e. time of minimal value in ?̂?(𝑡). Note that for 
core body temperature, we mainly considered bathyphase because it could be identified with 
a better precision than acrophase in most individuals. 90% confidence intervals for 𝜃𝑚𝑎𝑥  and 
𝜃𝑚𝑖𝑛 were evaluated and reported by applying 𝑁 = 1000 bootstrap trials(44). 
Telemetric Rest-Activity  
A recently developed 24-h harmonic Hidden Markov Model (HMM) approach(29) was fitted 
to the data to compute numerical quantifiers that were associated with circadian rhythm in 
rest-activity data. The HMM approach categorizes the actigraphy measurement into three 
states, namely inactive/rest, moderately active, and highly active, in a probabilistic way. We 
focused on the inactive/rest state, in particular the center-of-rest time over a 24-h span, 
which provided an estimation of the average center-of-rest time point during the recording 
period. 
Prediction of Core Body Temperature Bathyphase 
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The main aim of the study was to provide a method for the continuous and remote estimation 
of the individual subject’s bathyphase of the overt 24-hour rhythm in core body temperature. 
The potential for core temperature bathyphase to be predicted by DLMO, rest-activity, chest 
surface temperature, and chronotype as well as the subject’s characteristics was investigated 
using a multivariate linear regression model. Potential predictors were first explored via 
pairwise Spearman correlations. An initial regression model was formulated by considering 
all phases, together with sex, age, and BMI, as explanatory variables. A parsimonious 
regression model was then identified by a stepwise model selection procedure based on AICc 
criterion (corrected Akaike’s information criterion for small sample size) using the R function 
StepAICc (https://github.com/biometry/APES/blob/master/Data/Dormann2013/stepAICc.r ). 
 Significance of explanatory variables was also tested by two-tailed t-test where a possible 
significant effect was considered for p-values smaller than 0.1.  The distribution of the time 
distance between predicted and real core body temperature bathyphase measures 
(residuals) was computed to study the reliability of the prediction. A prediction accuracy of 
<1 h was considered as being precise enough for clinical applications. 
 
Study approval 
The protocol and subsequent amendments were approved by the Ethical Committee of 
Warwick University (REGO-2017-2055). The study was conducted according to the Helsinki 
Declaration(45). The subjects provided signed informed consent for their participation in the 
study. 
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Figure 1: Consort diagram 
Flow diagram showing the enrollment of participants, according to sex and age, and the 
variables that were measured with key features. DLMO stands for Dim Light Melatonin Onset. 
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Figure 2: Inter-subject variabilities in main circadian biomarkers.  
Panel A: Salivary melatonin profiles in two female participants (28 y.o. in gray and 30 y.o. in 
blue); the vertical dashed lines indicate Dim Light Melatonin Onset (DLMO), which differed by 
1h and 11 min between both subjects. The dark bar represents the mean sleep spans of both 
participants. Panel B: DLMO variations among 24 subjects. DLMO could not be computed for 
six participants, due to improper or lacking information on sampling times (N=5) or exposure 
to light > 50 lux within 30 min of sampling (N=1). The dark bar represents the mean sleep span 
of the 24 participants. Panel C: core body temperature patterns in the two same participants 
shown in panel A. Five-min aggregated data are displayed as dots; the solid curves illustrate 
the averaged 24-h profiles according to two-harmonic cosinor fitting. Bathyphases with 90% 
confidence intervals estimated by the bootstrap method are indicated with dashed lines and 
color bands. The dark bar represents the mean sleep span of both participants. Panel D: Core 
body temperature bathyphase (and 90% confidence interval) variations among the 33 
participants. The dark bar represents the mean sleep span of all participants. Panel E:  
Scatterplots and dashed regression line, with results from both Pearson and Spearman 
correlations between DLMO and core body temperature bathyphase for the 24 subjects. 
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Figure 3: Inter-subject variabilities in rest-activity and chest surface temperature.  
Panel A: representative examples of chronograms of chest surface temperature (top) and 
rest-activity (bottom) of two participants (blue, female 71 y.o.; gray, male 34 y.o.). Hourly 
aggregated data are shown with dots, with solid curves corresponding to Fourier fitting with 
harmonics estimated using Spectrum Resampling algorithm(28). The dark bars represent the 
participants respective sleeping spans. Panel B: Top, circadian activity state probability plot 
from harmonic HMM for a 78 y.o male participant illustrating the computation method of the 
center-of-rest time. Three activity states were assumed in the Hidden Markov Model, i.e. 
inactive state (blue), moderately active state (pink) and highly activity state (red). The three 
states probabilities sum up to 1. The “center-of-rest time” was computed as the gravity center 
of the inactive state probability profile (blue), as indicated with a dashed vertical black line. 
Bottom: Boxplot (5-95 percentiles) of the center-of-rest times in the 33 participants. The dark 
bar represents the mean sleep span of all 33 participants. Panel C: representative examples 
of the chest surface temperature of both same participants as in panel A. Five-min aggregated 
data are shown as dots and solid curves represent the averaged 24-h profiles using cosinor 
fitting. The dark bar represents the mean sleep span of both participants. Panel D: range of 
chest surface temperature acrophases (and 90% confidence limits estimated by bootstrap 
method) of the 24 participants displaying a 24-h rhythm (left) and the 9 participants with a 
dominant 12-h rhythm (right). The dark bar represents the mean sleep span of the 
corresponding participants. 
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Figure 4: Relations between measured and predicted core body temperature bathyphases 
in the 33 participants.  
Red stars indicate the computed bathyphases of core body temperature, with their respective 
90% confidence limits shown as horizontal limited lines, according to cosinor analysis of real 
measurements. Gray dots and bands represent the within-sample predicted bathyphases 
with corresponding 90% prediction bands, as computed using the INTime model. 
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Figure 5: Study picture 
Schematic description of the study design. GPRS stands for General Packet Radio Service. 
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